MAPS Statement on FDA Complete Response Letter on MDMA-Assisted Therapy for PTSD New Drug Application
FOR IMMEDIATE RELEASE: August 9, 2024| Multidisciplinary Association for Psychedelic Studies - MAPS
The global mental health and neuroscience communities are mourning the loss of Nolan Williams, M.D., who passed away on October 8, 2025. A brilliant, irreverent, and deeply compassionate physician-scientist, Dr. Williams was a Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab. To those who knew him best, he was far more than a pioneer — he was a devoted husband, an adoring father, and a man who approached life with curi...| maps.org
San Jose, CA | October 6, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is partnering with the HoloMind Institute to deliver its International Psychedelic Therapy Training Program in Poland, a first for the country. From October 6–12, 2025, 60 clinicians… Continue reading MAPS and HoloMind Institute Host International MDMA-Assisted Therapy Training in Poland| Multidisciplinary Association for Psychedelic Studies – MAPS
About MAPS| maps.org
Betty Aldworth and Ismail Lourido Ali bring decades of combined experience in drug policy leadership, psychedelic advocacy, and movement building| Multidisciplinary Association for Psychedelic Studies - MAPS
San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder (PTSD). Today, the FDA made this CRL publicly available for the first time, providing transparency into the agency’s decision-making process. … Continue reading MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy| Multidisciplinary Association for Psychedelic Studies – MAPS
August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization (CRO) for MJP2, a Phase 2 study examining inhaled cannabis for the treatment of Posttraumatic Stress Disorder (PTSD) in Veterans. MJP2 is funded by a $12.9 million grant… Continue reading MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans| Multidisciplinary Association for Psychedelic Studies – MAPS
Richard Lee, a pioneering activist who dedicated his life to ending the war on cannabis and to creating opportunities for dignity, education, and freedom, passed away on July 27 in Houston, Texas, from complications of cancer. He was 62. Paralyzed in a workplace accident in 1990, Lee discovered the healing potential of cannabis and transformed… Continue reading Remembering long-time California cannabis activist, Richard Lee| Multidisciplinary Association for Psychedelic Studies – MAPS
WASHINGTON, DC (August 14, 2025) — One year after the FDA’s denial of the New Drug Application for MDMA-assisted therapy for PTSD, the Multidisciplinary Association for Psychedelic Studies (MAPS) has issued an open letter to the U.S. Secretary of Health and Human Services (HHS), Robert F. Kennedy Jr., and Dr. Martin A. Makary, the Commissioner… Continue reading MAPS Urges Action: Open Letter to HHS Secretary and FDA Commissioner One Year After FDA Denial of MDMA-Assisted Therapy for PTSD| Multidisciplinary Association for Psychedelic Studies – MAPS
On Tuesday, the Senate officially confirmed Terrance Cole as the new Administrator of the Drug Enforcement Administration (DEA), marking the first permanent leadership appointment to the agency under President Trump’s second term. Cole’s confirmation comes at a pivotal moment, as the DEA faces mounting pressure to respond to the U.S. Department of Health and Human Services’ recommendation to reschedule cannabis. His leadership will be instrumental in determining how — and whether — ...| Multidisciplinary Association for Psychedelic Studies - MAPS
Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videos| Multidisciplinary Association for Psychedelic Studies - MAPS
DENVER, June 12, 2025 (GLOBE NEWSWIRE) — With growing recognition of psychedelics and plant medicines in therapeutic and scientific settings, it is a critical time to uplift and acknowledge the Indigenous wisdom and practices that preceded and guide today’s progress. Psychedelic Science 2025 (PS2025) honors these roots with a dedicated Plant Medicine Track that highlights spiritual, cultural,… Continue reading Plant Medicine Track at Psychedelic Science 2025 Spotlights Ancestral Wisdo...| Multidisciplinary Association for Psychedelic Studies – MAPS
FOR IMMEDIATE RELEASE: September 14, 2023| Multidisciplinary Association for Psychedelic Studies - MAPS
FOR IMMEDIATE RELEASE: December 13, 2023| Multidisciplinary Association for Psychedelic Studies - MAPS
We encourage you to read and follow maps.org/safety for information regarding MAPS Code of Ethics for Psychedelic Psychotherapy and our practices to create a culture of safety in the psychedelic community. | maps.org
Shaping Culture| Multidisciplinary Association for Psychedelic Studies - MAPS
FOR IMMEDIATE RELEASE: August 9, 2024| Multidisciplinary Association for Psychedelic Studies - MAPS
